PML-RARA mutations confer varying arsenic trioxide resistance

Dong-Mei Bai; Xiao-Feng Zheng

doi:10.1007/s13238-016-0356-4

PDF(1132 KB)

Protein Cell ›› 2017, Vol. 8 ›› Issue (4) : 296-301. DOI: 10.1007/s13238-016-0356-4

LETTER

PML-RARA mutations confer varying arsenic trioxide resistance

Dong-Mei Bai¹^,² ,
Xiao-Feng Zheng¹^,²

Author information +

History +

Cite this article

EndNote

Ris (Procite)

Bibtex

Download citation ▾

Dong-Mei Bai, Xiao-Feng Zheng. PML-RARA mutations confer varying arsenic trioxide resistance. Protein Cell, 2017, 8(4): 296‒301 https://doi.org/10.1007/s13238-016-0356-4

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	deThe H, ChomienneC, LanotteM, DegosL, DejeanA (1990) The t (15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus.Nature347:558–561 CrossRef Google scholar

[2]	GotoE, TomitaA, HayakawaF, AtsumiA, KiyoiH, NaoeT (2011) Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment.Blood118:1600–1609 CrossRef Google scholar

[3]	JeanneM, Lallemand-BreitenbachV, FerhiO, KokenM, Le BrasM, DuffortS, PeresL, BerthierC, SoilihiH, RaughtB (2010) PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.Cancer Cell18:88–98 CrossRef Google scholar

[4]

Lallemand-BreitenbachV, ZhuJ, PuvionF, KokenM, HonoreN, DoubeikovskyA, DuprezE, PandolfiPP, PuvionE, FreemontP (2001) Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation.J Exp Med193:1361–1371

CrossRef Google scholar

[5]	Lallemand-BreitenbachV, JeanneM, BenhendaS, NasrR, LeiM, PeresL, ZhouJ, ZhuJ, RaughtB, deThe H (2008) Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway.Nat Cell Biol10:547–555 CrossRef Google scholar

[6]	LiJ, ChenP, SinogeevaN, GorospeM, WerstoRP, ChrestFJ, BarnesJ, LiuY (2002) Arsenic trioxide promotes histone H3 phosphoacetylation at the chromatin of CASPASE-10 in acute promyelocytic leukemia cells.J Biol Chem277:49504–49510 CrossRef Google scholar

[7]	LiuJ, ZhuHH, JiangH, JiangQ, HuangXJ (2016) Varying responses of PML-RARA with different genetic mutations to arsenic trioxide.Blood127:243–250 CrossRef Google scholar

[8]	Lo-CocoF, AvvisatiG, VignettiM, ThiedeC, OrlandoSM, IacobelliS, FerraraF, FaziP, CicconiL, Di BonaE (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.N Engl J Med369:111–121 CrossRef Google scholar

[9]	RiceKL, deThe H (2014) The acute promyelocytic leukaemia success story: curing leukaemia through targeted therapies.J Intern Med276:61–70 CrossRef Google scholar

[10]	WangZY, ChenZ (2008) Acute promyelocytic leukemia: from highly fatal to highly curable.Blood111:2505–2515 CrossRef Google scholar

[11]	ZhangXW, YanXJ, ZhouZR, YangFF, WuZY, SunHB, LiangWX, SongAX, Lallemand-BreitenbachV, JeanneM (2010) Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.Science328:240–243 CrossRef Google scholar

[12]	ZhouGB, ZhangJ, WangZY, ChenSJ, ChenZ (2007) Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.Philos Trans R Soc Lond B Biol Sci362:959–971 CrossRef Google scholar

[13]	ZhuHH, HuangXJ (2014) Oral arsenic and retinoic acid for non-highrisk acute promyelocytic leukemia.N Engl J Med371:2239–2241 CrossRef Google scholar